BLV: lessons on vaccine development

Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, undergo long-term latency in a proportion of infected cells and thereby escape immune response. Since clearance of the virus is almost impossible once infection is established, the prim...

Full description

Bibliographic Details
Main Authors: Abdala, Alejandro Ariel, Alvarez, Irene, Brossel, Hélène, Calvinho, Luis Fernando, Carignano, Hugo, Franco, Lautaro Nahuel, Gazon, Hélène, Gillissen, Christelle, Hamaidia, Malik, Hoyos, Clotilde, Jacques, Jean-Rock, Joris, Thomas, Laval, Florent, Petersen, Marcos Iván, Porquet, Florent, Porta, Natalia Gabriela, Ruiz, Vanesa, Safari, Rogaiyeh, Suarez Archilla, Guillermo Alejandro, Trono, Karina Gabriela, Willems, Luc
Format: info:ar-repo/semantics/artículo
Language:Inglés
Published: BMC 2019
Subjects:
Online Access:https://retrovirology.biomedcentral.com/articles/10.1186/s12977-019-0488-8
http://hdl.handle.net/20.500.12123/6118
https://doi.org/10.1186/s12977-019-0488-8
_version_ 1855035617760509952
author Abdala, Alejandro Ariel
Alvarez, Irene
Brossel, Hélène
Calvinho, Luis Fernando
Carignano, Hugo
Franco, Lautaro Nahuel
Gazon, Hélène
Gillissen, Christelle
Hamaidia, Malik
Hoyos, Clotilde
Jacques, Jean-Rock
Joris, Thomas
Laval, Florent
Petersen, Marcos Iván
Porquet, Florent
Porta, Natalia Gabriela
Ruiz, Vanesa
Safari, Rogaiyeh
Suarez Archilla, Guillermo Alejandro
Trono, Karina Gabriela
Willems, Luc
author_browse Abdala, Alejandro Ariel
Alvarez, Irene
Brossel, Hélène
Calvinho, Luis Fernando
Carignano, Hugo
Franco, Lautaro Nahuel
Gazon, Hélène
Gillissen, Christelle
Hamaidia, Malik
Hoyos, Clotilde
Jacques, Jean-Rock
Joris, Thomas
Laval, Florent
Petersen, Marcos Iván
Porquet, Florent
Porta, Natalia Gabriela
Ruiz, Vanesa
Safari, Rogaiyeh
Suarez Archilla, Guillermo Alejandro
Trono, Karina Gabriela
Willems, Luc
author_facet Abdala, Alejandro Ariel
Alvarez, Irene
Brossel, Hélène
Calvinho, Luis Fernando
Carignano, Hugo
Franco, Lautaro Nahuel
Gazon, Hélène
Gillissen, Christelle
Hamaidia, Malik
Hoyos, Clotilde
Jacques, Jean-Rock
Joris, Thomas
Laval, Florent
Petersen, Marcos Iván
Porquet, Florent
Porta, Natalia Gabriela
Ruiz, Vanesa
Safari, Rogaiyeh
Suarez Archilla, Guillermo Alejandro
Trono, Karina Gabriela
Willems, Luc
author_sort Abdala, Alejandro Ariel
collection INTA Digital
description Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, undergo long-term latency in a proportion of infected cells and thereby escape immune response. Since clearance of the virus is almost impossible once infection is established, the primary goal is to achieve sterilizing immunity. Besides efficacy, safety is the major issue since vaccination has been associated with increased infection or reversion to pathogenicity. In this review, we discuss the different issues that we faced during the development of an efficient vaccine against bovine leukemia virus (BLV). We summarize the historical failures of inactivated vaccines, the efficacy and safety of a live-attenuated vaccine and the economical constraints of further industrial development.
format info:ar-repo/semantics/artículo
id INTA6118
institution Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina)
language Inglés
publishDate 2019
publishDateRange 2019
publishDateSort 2019
publisher BMC
publisherStr BMC
record_format dspace
spelling INTA61182019-10-16T11:44:57Z BLV: lessons on vaccine development Abdala, Alejandro Ariel Alvarez, Irene Brossel, Hélène Calvinho, Luis Fernando Carignano, Hugo Franco, Lautaro Nahuel Gazon, Hélène Gillissen, Christelle Hamaidia, Malik Hoyos, Clotilde Jacques, Jean-Rock Joris, Thomas Laval, Florent Petersen, Marcos Iván Porquet, Florent Porta, Natalia Gabriela Ruiz, Vanesa Safari, Rogaiyeh Suarez Archilla, Guillermo Alejandro Trono, Karina Gabriela Willems, Luc Vacuna Vacunación Retroviridae Virus Leucemia Bovina Vaccines Vaccination Bovine Leukaemia Virus Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, undergo long-term latency in a proportion of infected cells and thereby escape immune response. Since clearance of the virus is almost impossible once infection is established, the primary goal is to achieve sterilizing immunity. Besides efficacy, safety is the major issue since vaccination has been associated with increased infection or reversion to pathogenicity. In this review, we discuss the different issues that we faced during the development of an efficient vaccine against bovine leukemia virus (BLV). We summarize the historical failures of inactivated vaccines, the efficacy and safety of a live-attenuated vaccine and the economical constraints of further industrial development. EEA Rafaela Fil: Abdala, Alejandro Ariel. INTA. Estación Experimental Agropecuaria Rafaela; Argentina Fil: Alvarez, Irene. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Brossel, Hélène. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Calvinho, Luis Fernando. INTA. Estación Experimental Agropecuaria Rafaela; Argentina Fil: Carignano, Hugo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Tecnológicas; Argentina Fil: Franco, Lautaro. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Tecnológicas; Argentina Fil: Gazon, Hélène. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Gillissen, Christelle. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Hoyos, Clotilde. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Jacques, Jean-Rock. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Joris, Thomas. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Laval, Florent. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Petersen, Marcos Iván. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Tecnológicas; Argentina Fil: Porquet, Florent. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Porta, Natalia Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Tecnológicas; Argentina Fil: Ruiz, Vanesa. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Tecnológicas; Argentina Fil: Safari, Rogaiyeh. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica Fil: Suarez Archilla, Guillermo Alejandro. INTA. Estación Experimental Agropecuaria Rafaela; Argentina Fil: Trono, Karina Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Willems, Luc. University of Liège. Molecular and Cellular Epigenetics (GIGA) and Molecular Biology (TERRA); Bélgica 2019-10-16T11:40:42Z 2019-10-16T11:40:42Z 2019-10-07 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://retrovirology.biomedcentral.com/articles/10.1186/s12977-019-0488-8 http://hdl.handle.net/20.500.12123/6118 1742-4690 https://doi.org/10.1186/s12977-019-0488-8 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf BMC Retrovirology 16 : article number: 26 (2019)
spellingShingle Vacuna
Vacunación
Retroviridae
Virus Leucemia Bovina
Vaccines
Vaccination
Bovine Leukaemia Virus
Abdala, Alejandro Ariel
Alvarez, Irene
Brossel, Hélène
Calvinho, Luis Fernando
Carignano, Hugo
Franco, Lautaro Nahuel
Gazon, Hélène
Gillissen, Christelle
Hamaidia, Malik
Hoyos, Clotilde
Jacques, Jean-Rock
Joris, Thomas
Laval, Florent
Petersen, Marcos Iván
Porquet, Florent
Porta, Natalia Gabriela
Ruiz, Vanesa
Safari, Rogaiyeh
Suarez Archilla, Guillermo Alejandro
Trono, Karina Gabriela
Willems, Luc
BLV: lessons on vaccine development
title BLV: lessons on vaccine development
title_full BLV: lessons on vaccine development
title_fullStr BLV: lessons on vaccine development
title_full_unstemmed BLV: lessons on vaccine development
title_short BLV: lessons on vaccine development
title_sort blv lessons on vaccine development
topic Vacuna
Vacunación
Retroviridae
Virus Leucemia Bovina
Vaccines
Vaccination
Bovine Leukaemia Virus
url https://retrovirology.biomedcentral.com/articles/10.1186/s12977-019-0488-8
http://hdl.handle.net/20.500.12123/6118
https://doi.org/10.1186/s12977-019-0488-8
work_keys_str_mv AT abdalaalejandroariel blvlessonsonvaccinedevelopment
AT alvarezirene blvlessonsonvaccinedevelopment
AT brosselhelene blvlessonsonvaccinedevelopment
AT calvinholuisfernando blvlessonsonvaccinedevelopment
AT carignanohugo blvlessonsonvaccinedevelopment
AT francolautaronahuel blvlessonsonvaccinedevelopment
AT gazonhelene blvlessonsonvaccinedevelopment
AT gillissenchristelle blvlessonsonvaccinedevelopment
AT hamaidiamalik blvlessonsonvaccinedevelopment
AT hoyosclotilde blvlessonsonvaccinedevelopment
AT jacquesjeanrock blvlessonsonvaccinedevelopment
AT joristhomas blvlessonsonvaccinedevelopment
AT lavalflorent blvlessonsonvaccinedevelopment
AT petersenmarcosivan blvlessonsonvaccinedevelopment
AT porquetflorent blvlessonsonvaccinedevelopment
AT portanataliagabriela blvlessonsonvaccinedevelopment
AT ruizvanesa blvlessonsonvaccinedevelopment
AT safarirogaiyeh blvlessonsonvaccinedevelopment
AT suarezarchillaguillermoalejandro blvlessonsonvaccinedevelopment
AT tronokarinagabriela blvlessonsonvaccinedevelopment
AT willemsluc blvlessonsonvaccinedevelopment